Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney

The role of carrier-mediated transport in determining the pharmacokinetics of drugs has become increasingly evident with the discovery of genetic variants that affect expression and/or function of a given drug transporter. Drug transporters are expressed at numerous epithelial barriers, such as inte...

Full description

Saved in:
Bibliographic Details
Published inPharmacogenomics Vol. 9; no. 5; pp. 597 - 624
Main Authors Zaïr, Zoulikha M, Eloranta, Jyrki J, Stieger, Bruno, Kullak-Ublick, Gerd A
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.05.2008
Subjects
Animals
Humans
Intestines - physiology
Kidney - physiology
Liver - physiology
Organic Anion Transporters - genetics
Organic Anion Transporters - metabolism
Pharmacogenetics - methods
Online AccessGet full text

Cover

More Information
Summary:The role of carrier-mediated transport in determining the pharmacokinetics of drugs has become increasingly evident with the discovery of genetic variants that affect expression and/or function of a given drug transporter. Drug transporters are expressed at numerous epithelial barriers, such as intestinal epithelial cells, hepatocytes, renal tubular cells and at the blood-brain barrier. Several recent studies have associated alterations in substrate uptake with the presence of SNPs. Here, we summarize the current knowledge on the functional and phenotypic consequences of genetic variation in intestinally, hepatically and renally expressed members of the organic anion-transporting polypeptide family (OATPs; SLC21/SLCO family), the organic anion and organic cation transporters (OATs/OCTs; SLC22 family) and the peptide transporter-1 (PEPT1; SLC15 family).
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1462-2416
1744-8042
DOI:10.2217/14622416.9.5.597